L-asparaginase, cisplatin, Etoposide and Dexamethasone (LVDP) protocol in combination with radiotherapy for patinets with newly diagnosed NK/T cell lymphoma

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-TNC-12002353

Enrollment

Unknown

Registered

2012-05-30

Start date

2010-04-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Extranodal NK/T cell lymphoma, nasal type

Interventions

phase I/II:chemotherapy and radiotherapy

stage III/IV:chemotherapy and radiotherapy

Eligibility

Sex/Gender

All

Age

12 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Nasal type NK/T-cell lymphoma proved by pathology and immunohistology; 2. No chemotherapy or radiation was administered since diagnosis; 3. Performance status as ECOG 0-2 and no contraindication to chemotherapy; 4. Expectation of life was over 12 weeks; 5. Voluntary participation and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women; 2. Patients combined with any unstable systemic diseases; 3. Any conditions that the investigator regards to be not suitable for current study.

Design outcomes

Primary

Measure	Time frame
overall response rate;time to progress;one year and two year survival rate;	—

Secondary

Measure	Time frame
overall survival;Grade 3/4 toxicities;complete response rate;	—

Countries

China

Contacts

Public ContactLiqun Zou

hxlcyxy@163.com+86 18980601027

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 27, 2026